Promising New Compound Discovered to Inhibit SARS-CoV Nucleocapsid Protein
A new compound identified by researchers at the University of California, Berkeley, has been found to inhibit the SARS-CoV-2 nucleocapsid protein, an important target for potential therapeutics against COVID-19. This breakthrough discovery provides a promising new avenue for the development of drugs that could effectively combat the virus.
The new compound, named GT-56, was identified through a series of tests conducted to investigate the effectiveness of small molecules on the SARS-CoV-2 nucleocapsid protein. After screening more than 1,000 potential inhibitors, the researchers identified GT-56 as the most promising candidate. In laboratory experiments, it was found to be highly effective at blocking the activity of the nucleocapsid protein, which is essential for the virus to replicate. The team also demonstrated that GT-56 was able to effectively block the virus from replicating in cells, suggesting that it could be a useful therapeutic agent.
source: Phys.org